Terms: = Pancreatic cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Clinical Outcome
4 results:
1. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract] [Full Text] [Related]
2. pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
[TBL] [Abstract] [Full Text] [Related]
3. Role of Collagen Gel Droplet-Embedded Culture-Drug Sensitivity Testing (CD-DST) for Assessing the Sensitivity of Gastric cancer to Chemotherapy Drugs Combined with Other cancer Therapeutic Drugs.
Makino H; Nomura S; Kogo H; Wada N; Hayashi M; Yoshida H
J Nippon Med Sch; 2022 Aug; 89(4):412-421. PubMed ID: 35400719
[TBL] [Abstract] [Full Text] [Related]
4. Solid pseudopapillary tumor of the pancreas: A retrospective analysis of 36 cases from a single institution in India.
Singh P; Patel K; Ramakrishna B
Indian J Cancer; 2015; 52(3):439-42. PubMed ID: 26905162
[TBL] [Abstract] [Full Text] [Related]
